369 Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies

• Gustav Ullenhag,
• Anne Månsson Kvarnhammar,
• Charlotte Russell,
• Jeffrey Yachnin,
• Ana Carneiro,
• Dorte Nielsen,
• Kristoffer Staal Rohrberg,
• Lena Schultz,
• Erika Bågeman,
• Camilla Wennersten

Affiliations

Gustav Ullenhag

2Uppsala University Hospital, Uppsala, Sweden

Anne Månsson Kvarnhammar

6Alligator Bioscience AB, Lund, Sweden

Charlotte Russell

6Alligator Bioscience AB, Lund, Sweden

Jeffrey Yachnin

1Karolinska Institutet, Stockholm, Sweden

Ana Carneiro

3Skane University Hospital and Lund Uni., Lund, Sweden

Dorte Nielsen

4Herlev and Gentofte Hospital, Herlev, Denmark

Kristoffer Staal Rohrberg

5Rigshospitalet, University Hospital, Copenhagen, Denmark

Lena Schultz

6Alligator Bioscience AB, Lund, Sweden

Erika Bågeman

6Alligator Bioscience AB, Lund, Sweden

Camilla Wennersten

6Alligator Bioscience AB, Lund, Sweden